{Reference Type}: Journal Article
{Title}: Combined drug anti-deep vein thrombosis therapy based on platelet membrane biomimetic targeting nanotechnology.
{Author}: Xiao H;Meng X;Songtao Li ;Li Z;Fang S;Wang Y;Li J;Tang J;Ma L;
{Journal}: Biomaterials
{Volume}: 311
{Issue}: 0
{Year}: 2024 Jun 17
{Factor}: 15.304
{DOI}: 10.1016/j.biomaterials.2024.122670
{Abstract}: After orthopedic surgeries, such as hip replacement, many patients are prone to developing deep vein thrombosis (DVT), which in severe cases can lead to fatal pulmonary embolism or major bleeding. Clinical intervention with high-dose anticoagulant therapy inevitably carries the risk of bleeding. Therefore, a targeted drug delivery system that adjusts local DVT lesions and potentially reduces drug dosage and toxic side effects important. In this study, we developed a targeted drug delivery platelet-derived nanoplatform (AMSNP@PM-rH/A) for DVT treatment that can simultaneously deliver a direct thrombin inhibitor (DTI) Recombinant Hirudin (rH), and the Factor Xa inhibitor Apixaban (A) by utilizing Aminated mesoporous silica nanoparticles (AMSNP). This formulation exhibits improved biocompatibility and blood half-life and can effectively eliminate deep vein thrombosis lesions and achieve therapeutic effects at half the dosage. Furthermore, we employed various visualization techniques to capture the targeted accumulation and release of a platelet membrane (PM) coating in deep vein thrombosis and explored its potential targeting mechanism.